Navigation Links
A Novel Method For Measuring Interstitial Fluid Pressure In Cancer Tissues

In normal subcutaneous tissue, the interstitial fluid pressure (IFP) is negative, and so, when the subcutaneous tissue of an animal is exposed, fluid does not seep out. //By contrast, IFP is often increased in tumor tissue and forms a barrier against efficient drug delivery into the tumor.

Many anticancer drugs and antibodies used for treating patients with cancer are transported from the circulatory system through the interstitial space by convection (i.e. by streaming of a flowing fluid) rather than by diffusion. Increased tumor IFP causes inefficient uptake of therapeutic agents by decreasing convection. Cancer cells are therefore exposed to a lower effective concentration of therapeutic agents than normal cells, reducing treatment efficiency. Decreasing tumor IFP can thus improve drug delivery into the tumor.

There are several techniques described for IFP measurements, however, all of these require experience to use ramified instrumentation and surgical procedures. Drs Ugur Ozerdem, and Alan R. Hargens, from the La Jolla Institute for Molecular Medicine, and the University of California San Diego, USA, have recently developed a simplified procedure using a transducer-tipped catheter and a precision glide needle that allows reliable measurement of IFP in tumor tissues.

This novel procedure, using a polyurethane transducer-tipped catheter (Millar), allows reliable measurement of interstitial fluid pressure (IFP) in cancer tissues. Before and after each use, the transducer is calibrated at 37°C by a water column. After calibration, the transducer is passed through the lumen of a surgical needle. The sensor is kept in the lumen of the needle during penetration into the tumor. The sensor tip is then introduced into the center core of the tumor as the needle sleeve is withdrawn from the tumor surface.

This new technique, described in Microvascular Research (available online 31 August 2005), is simple and provides IFPs equal to
'"/>




Page: 1 2

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the ... reducing the costs of an auto insurance policy . ... get lower prices for their vehicle insurance policies. The safety a ... policy costs. Because of this, drivers should always carry a ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Salamon HealthDay Reporter , MONDAY, Feb. ... children with attention-deficit hyperactivity disorder may reveal insights ... condition, according to two new studies. In ... Center and the Kennedy Krieger Institute in Baltimore ...
... regions that are not well oxygenated. Tumor cells in ... usually resistant to the death-inducing effects of chemotherapeutics. But ... Kingdom, have identified a compound (ABT-737) that induces human ... undergo a form of cell death known as apoptosis. ...
... is available in French . Montreal, February ... adage: A family that plays together stays together. Researchers from ... can maintain close ties with their adult grandchildren. True to ... bonds. "Leisure is vital in the formation of ...
... of Nephrology (ASN) recently launched the first mobile edition ... News highlights emerging trends in kidney health and disease. ... the mobile edition of ASN Kidney News, a free ... and updates, and helps kidney professionals and others access ...
... HealthDay Reporter , SUNDAY, Feb. 13 (HealthDay News) -- ... especially berries, may be protecting themselves from developing Parkinson,s ... berries, flavonoids are found in a variety of foods ... have been touted as protective against some diseases because ...
... (HealthDay News) -- A quick, simple test done on the ... a new study says. The screening -- known as ... that can fail to assess a wide range of brain ... School of Medicine. For this test, athletes are asked ...
Cached Medicine News:Health News:Hand Movements May Give Clues to ADHD Severity 2Health News:Hand Movements May Give Clues to ADHD Severity 3Health News:Hand Movements May Give Clues to ADHD Severity 4Health News:Playtime helps bind generations 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Quick, Simple Test Can Detect Concussion in Athletes 2
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Va., June 20, 2007 /PRNewswire/ -- ... the successful completion of,pharmacokinetic and pharmacodynamic ... long-acting interferon beta and,long-acting erythropoietin. , ... superb durability of the long-acting,proteins, indicating ...
... MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB),today ... Albumin Conjugate for the treatment of,Type 2 ... Scientific,Sessions of the American Diabetes Association (ADA) to ... The ADA's annual,Scientific Sessions meeting is one ...
Cached Medicine Technology:Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 2Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 3Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 4ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting 2ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting 3
A conservative, cost effective alternative to total knee replacement for patients with osteoarthritis primarily confined to one compartment....
...
... The Maxim Knee employs titanium alloy ... an excellent fixation surface. Biomet's ArCom ... durable and proven bearing material. The ... full inter-changeability. Modular tibial components offer ...
... The Natural-Knee family is a ... with over 14 years of proven ... several innovative features including a proprietary ... fixation in active patients, a unique ...
Medicine Products: